Cervical Cancer Screening.


Journal Article (Review)

Cervical cancer screening in the United States has accompanied profound decreases in cancer incidence and mortality over the last half century. Two screening strategies are currently endorsed by US-based guideline groups: (1) triennial cytology for women aged 21 to 65 years, and (2) triennial cytology for women aged 21 to 29 years followed by cytology plus testing for high-risk human papillomavirus types every 5 years for women aged 30 years and older. Providing women with affordable, easily accessible screening, follow-up of abnormal tests, and timely treatment will result in the greatest impact of screening on cervical cancer incidence and mortality.

Full Text

Duke Authors

Cited Authors

  • Sawaya, GF; Huchko, MJ

Published Date

  • July 2017

Published In

Volume / Issue

  • 101 / 4

Start / End Page

  • 743 - 753

PubMed ID

  • 28577624

Pubmed Central ID

  • 28577624

Electronic International Standard Serial Number (EISSN)

  • 1557-9859

Digital Object Identifier (DOI)

  • 10.1016/j.mcna.2017.03.006


  • eng

Conference Location

  • United States